Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity - Trial NCT06215196
Access comprehensive clinical trial information for NCT06215196 through Pure Global AI's free database. This phase not specified trial is sponsored by S.LAB (SOLOWAYS) and is currently Completed. The study focuses on Overweight and Obesity. Target enrollment is 81 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
S.LAB (SOLOWAYS)
Timeline & Enrollment
N/A
Apr 14, 2023
Aug 20, 2023
Primary Outcome
Percentage change in body weight from baseline,Achievement of a reduction in body weight of 5% or more from baseline.
Summary
This clinical trial investigated the combined effects of Semaglutide and a fiber supplement
 (glucomannan, inulin, psyllium) on weight loss in adults with overweight or obesity.
 Participants, aged 18-65 with a BMI ≥30 or ≥27 with comorbidities, were randomized into two
 groups: one receiving Semaglutide with active fiber supplements and the other with
 Semaglutide and placebo, over a 180-day period. Key endpoints included percentage change in
 body weight, BMI, body composition, safety, and appetite control, with a focus on evaluating
 the additive effects of dietary fibers in enhancing Semaglutide's efficacy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06215196
Non-Device Trial